Sitosterol could lower cholesterol levels and alleviate HFD-induced non-alcoholic fatty liver disease through ameliorating levels of hepatic total lipids, triacylglycerols, cholesterol and liver histopathology, decreasing levels of intestinal bile acids, and increasing the expression of genes involved in lipid metabolism, including HMGCoAR, ABCG5, peroxisome proliferator-activated receptor-α (PPAR-α), and decreasing the expression of CD36 (65). The gene discussed is ABCG5; the disease is metabolic dysfunction-associated steatotic liver disease.